This enduring activity highlights two expert faculty’s discussion on the evidence for available and emerging TYK2 inhibitors in psoriatic disease and to improve their competence in the individualized use of oral small-molecule therapies to improve outcomes for their patients. As a result of this educational curriculum, learners will be better able to: 1. Recognize how NPs and PAs can help address barriers to care and enhance outcomes for patients with moderate to severe plaque psoriasis; 2. Differentiate TYK2 signaling from JAK pathways and explain the relevance of these distinctions in clinical outcomes; 3. Evaluate the impact of emerging data on TYK2 inhibitors in shaping therapeutic strategies for psoriatic disease; and, 4. Apply strategies for aligning TYK2 inhibitor therapy with patient needs and multidisciplinary care plans. Learners have access to downloadable materials.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 27 Trinity Place, Suite 185
Pricing
99% of listed courses are free
156 of 157 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General Internal Medicine
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Oncology
- Nephrology
- Neurocritical Care
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Urology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Microlearning
- includes Online course / module
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedDec 6, 2025
-
Last day to claim creditDec 6, 2026 8 weeks left
-
Answers in CME Inc. (AiCME) Small Molecules, Big Decisions: Where Do TYK2 Inhibitors Fit in Psoriasis Treatment?
-
Answers in CME Inc. (AiCME) Redefining Oral Therapy in Psoriasis: TYK2 Inhibition in Focus
-
Answers in CME Inc. (AiCME) The Dermatology-Rheumatology Psoriatic Playbook: Advancing Care with Novel Oral Therapies in the Evolving PsA Landscape
-
Partners for Advancing Clinical Education Tuning In to TYK2: Innovation in Oral Psoriasis Treatment for NPs and PAs
-
PRIME Education, Inc. (PRIME®) An Expert TheraTalk on the Next Wave in Psoriasis Treatment: From Mechanistic Pathways to Clinical Practice
-
Med Learning Group TYK, Tock Time to Rethink PsA Management: Exploring the Potential Role of Emerging Oral Therapies
